Coeptis Therapeutics regains Nasdaq compliance

Coeptis Therapeutics announced that it has received a notification letter from the Nasdaq Hearings Panel granting its request for continued listing on The Nasdaq Stock Market through January 15, 2025, subject to the company demonstrating compliance with Nasdaq Listing Rule 5550(a)(2). On September 12th, Coeptis presented a plan before the Panel to address the minimum bid price requirement, including its intent to implement a reverse stock split. The Panel issued its decision on September 17th with the extension granted.